产品说明书
TGR5 Receptor Agonist
 |
同义名 : | CCDC;TGR5;MDK00245 |
| CAS号 : | 1197300-24-5 | |
| 货号 : | A672110 | |
| 分子式 : | C18H14Cl2N2O2 | |
| 纯度 : | 99%+ | |
| 分子量 : | 361.222 | |
| MDL号 : | MFCD17169972 | |
| 存储条件： |
粉末 Sealed in dry,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 50 mg/mL(138.42 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | TGR5 Receptor Agonist (CCDC), a robust agonist of Takeda G protein-coupled receptor 5 (TGR5; GPCR19), demonstrates enhanced effectiveness in U2-OS and melanophore cells with pEC50s of 6.8 and 7.5, respectively. This agonist triggers peripheral and central sensitivity to bladder distension in mice and elevates intracellular Ca2+ levels. It also reduces food consumption and heightens insulin sensitivity in diet-induced obese mice. The TGR5 Receptor Agonist is applicable in studies on diabetes, bladder hypersensitivity, and obesity control[1][2][3][4]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT01674946 | Echolocation | Phase 1 | Completed | - | Switzerland ... 展开 >> University Hospital Basel, Phase 1 Research Unit Basel, Switzerland, 4031 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.77mL 0.55mL 0.28mL |
13.84mL 2.77mL 1.38mL |
27.68mL 5.54mL 2.77mL |
